EcoDrugPlus

P2x Purinoceptor 3-Like

Ensembl ID : ENSOKIG00005014474
Gene Symbol: LOC109893848
3 Cross references
191 Possible Orthologues:

P2x Purinoceptor 3-Like

Ensembl ID : ENSOKIG00005022936
Gene Symbol: LOC109880678
3 Cross references
186 Possible Orthologues:

P2x Purinoceptor 4-Like

Ensembl ID : ENSOKIG00005041503
Gene Symbol: LOC109878126
3 Cross references
185 Possible Orthologues:

P2x Purinoceptor 4-Like

Ensembl ID : ENSOKIG00005042601
Gene Symbol: LOC109895773
3 Cross references
185 Possible Orthologues:

P2y Purinoceptor 12

Ensembl ID : ENSOKIG00005039434
Gene Symbol: LOC109905891
3 Cross references
174 Possible Orthologues:

P2y Purinoceptor 12

Ensembl ID : ENSOKIG00005017040
Gene Symbol: LOC109881377
3 Cross references
174 Possible Orthologues:

Ptk6 Protein Tyrosine Kinase 6b

Ensembl ID : ENSOKIG00005004821
Gene Symbol: PTK6B
1 Cross references
159 Possible Orthologues:

Pim-3 Proto-Oncogene, Serine/threonine Kinase

Ensembl ID : ENSOKIG00005031937
Gene Symbol: PIM3
3 Cross references
166 Possible Orthologues:

Pim-3 Proto-Oncogene, Serine/threonine Kinase

Ensembl ID : ENSOKIG00005020531
Gene Symbol: PIM3
3 Cross references
166 Possible Orthologues:

Rac-Beta Serine/threonine-Protein Kinase

Ensembl ID : ENSOKIG00005018626
Gene Symbol: LOC109876052
2 Cross references
190 Possible Orthologues:

Rac-Beta Serine/threonine-Protein Kinase

Ensembl ID : ENSOKIG00005004524
Gene Symbol: LOC109905880
3 Cross references
190 Possible Orthologues:

Rac-Beta Serine/threonine-Protein Kinase

Ensembl ID : ENSOKIG00005038455
Gene Symbol: LOC109878741
3 Cross references
190 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).